▶ Click here for a larger view
In the first half of this year, the public offering of SK Bioscience, a vaccine specialized company that is considered a major IPO, is drawing attention.
According to the financial investment industry on the 1st, SK Bioscience will begin the process of applying for public offering stocks starting from the forecast of demand for institutional investors to determine the public offering price on the 3rd to 4th.
Based on the public offering price released on the day, the company will be listed on the stock market on the 18th after a subscription to general public offering stocks on the 9th to 10th.
SK Bioscience is a vaccine company spun off by SK Chemicals in July 2018, compared to SK Biopharm, which was listed last year.
It was highlighted that SK Biopharm, a new drug developer, was the first domestic pharmaceutical company to obtain approval for direct marketing of its own new drug from the US Food and Drug Administration (FDA). SK Bioscience is attracting attention because it is a vaccine development and consignment manufacturer in the corona19 phase.
Corona 19 vaccine candidates’NBP2001′ and’GBP510′ developed by themselves have entered clinical trials.
It signed a contract with AstraZeneca to produce undiluted vaccine candidates and finished drugs, and also signed an antigen development, production and global supply contract with NovaVax. Besides these, it is known that other companies also receive love calls.
As a result, expectations for so-called’tasang’ are rising for SK Bioscience, which is also rising to the price limit following SK Biopharm.
SK Bioscience’s total number of public offerings is 22.95 million shares, the desired price for offering is 49,000 won to 65,000 won, and the offering amount is at least 1.124.5 billion won.
There are some points that individual investors should check when making IPO investments.
First, in November of last year, the allocation of public offering shares to general subscribers was improved, and the amount of allocation increased. Accordingly, the equalization method and the range of the allocation amount applied when allocating public offering shares to general subscribers for each company may differ.
In other words, it is necessary to confirm the allocation amount by type of investor (institutional investors, general subscribers, employee stock ownership association), subscription and allocation methods (collective, separate, multiple, etc.), and the distribution method of shortfalls.
The detailed verification method can be obtained through the’Securities Report’ or the’Investment Prospectus’ (Part 1 Recruitment or Sales → General Information on Recruitment or Sales) at the time of listing. Assignments)
Listed companies may not generate profits within a short period of time after listing.
The main items to be checked are the type of special listing, application requirements, and whether or not the conditions for designating management items are suspended. In addition, at the end of the period for the commitment of institutional investors, the amount allocated to institutional investors may spill into the market at a time, which may negatively affect the stock price. Therefore, it is necessary to check the quantity and period of the commitment to hold, and the number of stocks that can be circulated after listing.
Along with this, it is explained that concerns over public offering bubbles should also be noted.
Park Jae-heung, deputy director of the disclosure review office of the Financial Supervisory Service, stressed, “Even if the IPO market interest is hot and the offering price is decided high, we do not guarantee high returns after listing.” . In fact, eight companies (14.3%) whose stock prices fell below the public offering price at the end of the year out of 56 companies whose offering price was above the top last year.
[류영상 매경닷컴 기자 [email protected]]
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]